Philippe Szapary

10.4k total citations · 3 hit papers
68 papers, 7.7k citations indexed

About

Philippe Szapary is a scholar working on Immunology, Genetics and Epidemiology. According to data from OpenAlex, Philippe Szapary has authored 68 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Immunology, 21 papers in Genetics and 17 papers in Epidemiology. Recurrent topics in Philippe Szapary's work include Psoriasis: Treatment and Pathogenesis (26 papers), Inflammatory Bowel Disease (21 papers) and Dermatology and Skin Diseases (16 papers). Philippe Szapary is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (26 papers), Inflammatory Bowel Disease (21 papers) and Dermatology and Skin Diseases (16 papers). Philippe Szapary collaborates with scholars based in United States, Canada and Belgium. Philippe Szapary's co-authors include Daniel J. Rader, Kristian Reich, LeAnne T. Bloedon, Newman Yeilding, Shu Li, Richard G. Langley, Kim Papp, Mark Lebwohl, Cynthia Guzzo and Gary D. Foster and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Philippe Szapary

64 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial of a Low-Carbohydrate Diet for Obesity

2003 1.2k citations Gary D. Foster, Holly R. Wyatt et al. New England Journal of Medicine profile →
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

2008 1.1k citations Kim Papp, Richard G. Langley et al. profile →
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

2019 787 citations William J. Sandborn, Jewel Johanns et al. New England Journal of Medicine profile →

Peers

Philippe Szapary

IMMUN

PHYSI

DERMA

GENET

EPIDE

Paolo Gisondi Italy

Roberto Corrocher Italy

Jeannette Bigler United States

Melinda Gooderham Canada

Kari Punnonen Finland

Niels Grunnet Denmark

Martin Lipkin United States

Paul A.M. van Leeuwen Netherlands

Stimson P. Schantz United States

T. Nikkari Finland

Paolo Gisondi Italy

Philippe Szapary

5.8k ×1.5

IMMUN

782 ×0.4

PHYSI

3.3k ×1.8

DERMA

343 ×0.2

GENET

985 ×0.8

EPIDE

Citations per year, relative to Philippe Szapary Philippe Szapary (= 1×) peers Paolo Gisondi

Countries citing papers authored by Philippe Szapary

Since Specialization

Citations

This map shows the geographic impact of Philippe Szapary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Szapary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Szapary more than expected).

Fields of papers citing papers by Philippe Szapary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Szapary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Szapary. The network helps show where Philippe Szapary may publish in the future.

Co-authorship network of co-authors of Philippe Szapary

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Szapary. A scholar is included among the top collaborators of Philippe Szapary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Szapary. Philippe Szapary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adedokun, Omoniyi J., Zhenhua Xu, Christopher Gasink, et al.. (2018). Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 154(6). 1660–1671. 179 indexed citations

Rutgeerts, Paul, Christopher Gasink, Daphne Chan, et al.. (2018). Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease. Gastroenterology. 155(4). 1045–1058. 115 indexed citations

Zhuang, Yanli, César A. Calderón, Stanley J. Marciniak, et al.. (2016). First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. European Journal of Clinical Pharmacology. 72(11). 1303–1310. 65 indexed citations

Landells, Ian, Colleen Marano, Shu Li, et al.. (2015). Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. Journal of the American Academy of Dermatology. 73(4). 594–603. 166 indexed citations

Tsai, Tsen‐Fang, Vincent Ho, Michael Song, et al.. (2012). The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. British Journal of Dermatology. 167(5). 1145–1152. 65 indexed citations

Foster, Gary D., Stephanie S. Vander Veur, Tracy L. Oliver, et al.. (2012). A randomized trial of the effects of an almond-enriched, hypocaloric diet in the treatment of obesity. American Journal of Clinical Nutrition. 96(2). 249–254. 82 indexed citations

Kimball, Alexa B., Kim Papp, Yasmine Wasfi, et al.. (2012). Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study. Journal of the European Academy of Dermatology and Venereology. 27(12). 1535–1545. 162 indexed citations

Yeilding, Newman, Philippe Szapary, Carrie Brodmerkel, et al.. (2012). Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives – an update. Annals of the New York Academy of Sciences. 1263(1). 1–12. 22 indexed citations

Hu, Chuanpu, Philippe Szapary, Newman Yeilding, & Honghui Zhou. (2011). Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure–response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis. Journal of Pharmacokinetics and Pharmacodynamics. 38(2). 237–260. 34 indexed citations

10.

Yeilding, Newman, Philippe Szapary, Carrie Brodmerkel, et al.. (2011). Development of the IL‐12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Annals of the New York Academy of Sciences. 1222(1). 30–39. 60 indexed citations

11.

Gordon, Kenneth B., Kim Papp, Richard G. Langley, et al.. (2011). Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. Journal of the American Academy of Dermatology. 66(5). 742–751. 110 indexed citations

12.

Lebwohl, Mark, Craig L. Leonardi, C.E.M. Griffiths, et al.. (2011). Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. Journal of the American Academy of Dermatology. 66(5). 731–741. 82 indexed citations

13.

Iqbal, Nayyar, Serena Cardillo, Sheri Volger, et al.. (2009). Chromium Picolinate Does Not Improve Key Features of Metabolic Syndrome in Obese Nondiabetic Adults. Metabolic Syndrome and Related Disorders. 7(2). 143–150. 58 indexed citations

14.

Elliott, Michael R., Jacqueline Benson, Marion Blank, et al.. (2009). Ustekinumab: Lessons Learned from Targeting Interleukin‐12/23p40 in Immune‐Mediated Diseases. Annals of the New York Academy of Sciences. 1182(1). 97–110. 66 indexed citations

15.

Ky, Bonnie, Anne Burke, Sotirios Tsimikas, et al.. (2008). The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology. 51(17). 1653–1662. 90 indexed citations

16.

Pellizzon, Michael, Jeffery T. Billheimer, LeAnne T. Bloedon, Philippe Szapary, & Daniel J. Rader. (2007). Flaxseed Reduces Plasma Cholesterol Levels in Hypercholesterolemic Mouse Models. Journal of the American College of Nutrition. 26(1). 66–75. 48 indexed citations

17.

Bloedon, LeAnne T. & Philippe Szapary. (2004). Flaxseed and Cardiovascular Risk. Nutrition Reviews. 62(1). 18–27. 149 indexed citations

18.

Szapary, Philippe & Daniel J. Rader. (2004). The triglyceride–high-density lipoprotein axis: An important target of therapy?. American Heart Journal. 148(2). 211–221. 69 indexed citations

19.

Foster, Gary D., Holly R. Wyatt, James O. Hill, et al.. (2003). A Randomized Trial of a Low-Carbohydrate Diet for Obesity. New England Journal of Medicine. 348(21). 2082–2090. 1203 indexed citations breakdown →

20.

Szapary, Philippe, LeAnne T. Bloedon, & Gary D. Foster. (2003). Physical activity and its effects on lipids. Current Cardiology Reports. 5(6). 488–493. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact